Drug

Danvilostomig clinical trials

studies test it: 11
open now: 7
in phase 3: 0
first study started: 2020

Keep track of what changes. Save the danvilostomig studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

SI-B003: 11

Studies by the year they started

11 studies that test it; most in 2023 (8)

Studies that test danvilostomig, by start year
Year	Studies
2020	1
2023	8
2024	2

By phase

A phase 1/2 study counts in both.

Phase 1: 3
Phase 2: 10

What it is tested for

Each study’s main condition, where its own words name it.

Squamous Cell Carcinoma of Head and Neck: 3
Carcinoma, Non-Small-Cell Lung: 2
Small Cell Lung Carcinoma: 1
Breast Neoplasms: 1
Esophageal Neoplasms: 1
Uterine Cervical Neoplasms: 1

Who runs them

Industry 11 · Other 0

Sichuan Baili Pharmaceutical Co., Ltd. (11)

Often tested with

Tested in the same studies.

Izalontamab brengitecan (7) · Izalontamab (2) · Immune Checkpoint Inhibitors (1)

Studies

Open first, then newest update. How each study uses danvilostomig is read from its arms, and is right about nine times in ten.

Testing it · 11

Codes

What other systems call danvilostomig · ClinicalTrials.gg INT016068

UNII (FDA) B4Q67YX49QDANVILOSTOMIGOne source FDA
NCI Thesaurus C178449DanvilostomigOne source FDA

System	Code	Name there	Checked by
UNII (FDA)	B4Q67YX49Q	DANVILOSTOMIG	One source FDA
NCI Thesaurus	C178449	Danvilostomig	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.